Summit's Cancer Drug Rivals Keytruda

Summit Therapeutics is developing ivonescimab, a bispecific antibody that demonstrates potential to surpass the efficacy of checkpoint inhibitors like Keytruda. A phase 3 study in China showed ivonescimab outperformed Keytruda in patients with non-small cell lung cancer.

This promising drug is currently in U.S. phase 3 trials for lung and colorectal cancer, with projected worldwide sales reaching $4.4 billion by 2030 and peak sales potentially hitting $53 billion. Ivonescimab holds patent exclusivity in the U.S. until 2039, offering a long commercial runway.

Investors who backed Summit Therapeutics and Madrigal Pharmaceuticals over the last three years have experienced substantial gains, with Summit surging 2,280% and Madrigal up 631%. Continued positive developments from late-stage studies and regulatory submissions are anticipated to further influence Summit's stock.